Vanda Pharmaceuticals
Washington, District Of Columbia, United States · Biopharma, Biotechnology, Health Care
Vanda is a leading global biopharmaceutical company focused on the development and commercialization of innovative therapies to address high unmet medical needs and improve the lives of patients.
Key facts
- Headquarters
- Washington, District Of Columbia, United States
- Employees
- Unknown
- Industries
- Biopharma, Biotechnology, Health Care
- Status
- Public (VNDA)
- Website
- vandapharma.com
- Company page
Recent activity at Vanda Pharmaceuticals
- : GW Athletics partners with Vanda Pharmaceuticals for jersey patch collaboration. (date Fundz recorded it)
- : Vanda Pharmaceuticals Inc. Announces Resignation of Senior Executive
- : SEC 8-K (5.02): On April 22, 2026, Vanda Pharmaceuticals Inc. expanded its Board of Directors from six to seven members, appointing Charles C. Duncan, Ph.D., as the new director to fill the newly created vacancy. Dr. Duncan will serve as a Class II director, with his term expiring at the company's 2026 annual meeting of stockholders. As part of his appointment, he was granted a restricted stock unit award valued at $390,000, vesting in four equal installments, beginning April 22, 2027, while he remains on the Board. Additionally, Dr. Duncan will receive an annual fee of $50,000 payable quarterly, and upon each annual meeting, he may be eligible for an additional restricted stock unit award valued at $260,000. The compensation terms and conditions suggest a strategic move by the company to enhance its governance with experienced leadership, particularly amid potential business developments.
- : SEC 8-K (5.02): On March 29, 2026, Timothy Williams resigned from his position as Senior Vice President, General Counsel and Secretary at Vanda Pharmaceuticals Inc., effective April 10, 2026. This decision was made as he intends to pursue other opportunities. The resignation reflects a significant change in the management structure of the company, potentially impacting corporate governance and strategic direction. The filing confirms the company's commitment to timely reporting of such changes as required by the SEC.
- : SEC 8-K (5.02): On March 29, 2026, Timothy Williams notified Vanda Pharmaceuticals Inc. of his resignation as the Company’s Senior Vice President, General Counsel and Secretary. His resignation will be effective as of April 10, 2026, as he seeks to pursue other endeavors. This change in the executive team may have implications for the Company's legal and governance strategies moving forward, particularly given Williams' senior role. The Company will need to transition responsibilities and may identify a successor in the coming weeks.
- : SEC 8-K (5.02): On March 29, 2026, Timothy Williams resigned from his position as Senior Vice President, General Counsel, and Secretary of Vanda Pharmaceuticals Inc., with his resignation effective on April 10, 2026. His decision to leave the company is to pursue other endeavors. This leadership change may impact the company's governance, particularly in legal and compliance matters, following his departure.
- : SEC 8-K (7.01): On March 10, 2026, Vanda Pharmaceuticals Inc. disclosed its pricing and commercial strategy for its FDA-approved drug NEREUS TM during an interview with its President and CEO, Mihael Polymeropoulos, on Fox Business. The discussion highlighted the development of NEREUSRX TM, a direct-to-consumer channel for accessing NEREUS TM, which is set to be available in the upcoming months. This strategic initiative indicates Vanda's expansion in the market for motion-induced vomiting prevention products, aiming to enhance consumer access. The event occurred on the same day it was reported, emphasizing its immediate relevance to stakeholders.
- : SEC 8-K (7.01): On March 10, 2026, Mihael Polymeropoulos, M.D., President, CEO, and Chairman of Vanda Pharmaceuticals Inc., discussed the company's pricing and commercial strategy for NEREUS TM, a drug approved by the FDA for preventing motion-induced vomiting. He announced the upcoming development of NEREUSRX TM, which will provide direct-to-consumer access to NEREUS TM, set to launch in the next couple of months. This strategic move indicates Vanda's commitment to expanding its market reach and improving accessibility to its new product.
- : SEC 8-K (8.01): On February 20, 2026, Vanda Pharmaceuticals Inc. announced via a press release that the U.S. Food and Drug Administration approved their drug Bysanti TM (milsaperidone) for the acute treatment of manic or mixed episodes associated with bipolar I disorder in adults and for the treatment of schizophrenia in adults. This approval represents a significant milestone for Vanda, potentially enhancing their product portfolio and offering new treatment options to patients suffering from these mental health conditions. The approval date, February 20, 2026, is noted as key for stakeholders, and further details are provided in the attached exhibit.
- : SEC 8-K (8.01): On February 20, 2026, Vanda Pharmaceuticals Inc. announced that the U.S. Food and Drug Administration (FDA) has approved Bysanti TM (milsaperidone) for the acute treatment of manic or mixed episodes associated with bipolar I disorder in adults, as well as for the treatment of schizophrenia in adults. This approval represents a significant advancement in the treatment options for these mental health conditions, potentially leading to broader market access and enhanced revenue opportunities for Vanda. The press release detailing the approval is attached as Exhibit 99.1. The strategic implications of this approval could positively impact Vanda's positioning in the psychiatric pharmaceutical market.
Dates are the day the event happened, taken from the announcement or SEC filing, unless a row says otherwise.
Leadership
- Scott Howell, Chief People Officer ◆ 300+ Employees ◆ 4 Countries ◆ $250M in Revenue
- Timothy Williams, General Counsel
Verified email and direct lines for Vanda Pharmaceuticals’s decision-makers are on Fundz. See plans or book a 15-minute walkthrough.
Employee benefit plans
Vanda Pharmaceuticals files 5 employee benefit plans with the U.S. Department of Labor, including a retirement plan. The next plan year renews in Dec 2026.
Vanda Pharmaceuticals in the news
- Vanda Pharmaceuticals Announces FDA Approval of NEREUS™ (tradipitant) for the Prevention of Vomiting Induced by Motion: A Historic Scientific Milestone in the Prevention of Motion Sickness - PR Newswire (Dec 30, 2025)
- Vanda Pharmaceuticals Reports First Quarter 2026 Financial Results - PR Newswire (May 06, 2026)
- Vanda Pharmaceuticals Reports Second Quarter 2026 Financial Results - PR Newswire (Aug 05, 2026)
- Vanda Pharmaceuticals Announces FDA Rare Pediatric Disease Designation for Investigational Therapy for Charcot-Marie-Tooth Disease Type 2S - PR Newswire (Jul 07, 2026)
- Vanda Pharmaceuticals Reports Fourth Quarter and Full Year 2024 Financial Results - PR Newswire (Feb 13, 2025)
- Vanda Pharmaceuticals Reports Positive Results for Tradipitant in Preventing GLP-1 Induced Nausea and Vomiting - PR Newswire (Nov 17, 2025)
- Vanda Pharmaceuticals Reports First Quarter 2025 Financial Results - PR Newswire (May 07, 2025)
- Vanda Pharmaceuticals Announces FDA Approval of BYSANTI™ (milsaperidone) for the treatment of Bipolar I Disorder and Schizophrenia - A New Chemical Entity Opening New Horizons in Psychiatric Innovation - PR Newswire (Feb 20, 2026)
Companies similar to Vanda Pharmaceuticals
- Abivax · Biopharma, Biotechnology, Health Care, Medical, Pharmaceutical, Therapeutics
- Delta-Fly Pharma · Biopharma, Biotechnology, Health Care, Medical, Pharmaceutical, Therapeutics
- Decoy Therapeutics Inc. · Biopharma, Biotechnology, Health Care, Medical, Pharmaceutical, Therapeutics
- Kairos Pharma Ltd · Biopharma, Biotechnology, Health Care, Medical, Pharmaceutical, Therapeutics
- Pharma Two B Ltd · Biopharma, Biotechnology, Health Care, Medical, Pharmaceutical, Therapeutics
About Vanda Pharmaceuticals: questions and answers
What does Vanda Pharmaceuticals do?
Vanda is a leading global biopharmaceutical company focused on the development and commercialization of innovative therapies to address high unmet medical needs and improve the lives of patients.
Where is Vanda Pharmaceuticals headquartered?
Vanda Pharmaceuticals is headquartered in Washington, District Of Columbia, United States.
What is the latest news on Vanda Pharmaceuticals?
On Jun 26, 2026, GW Athletics partners with Vanda Pharmaceuticals for jersey patch collaboration.
Is Vanda Pharmaceuticals a public company?
Yes. Vanda Pharmaceuticals is publicly traded under the ticker VNDA.
Source: Fundz records from SEC filings, press releases and company announcements. How Fundz measures data accuracy